Damon Runyon Researchers

Meet Our Scientists
Harshabad Singh, MBBS

Pancreatic cancer is the third most common cause of cancer-related deaths in the United States. This cancer is normally treated with a combination of different chemotherapies. While treatment is initially effective, the cancer quickly learns how to evade therapy and regrow. Using novel assays to analyze individual pancreatic cancer cells obtained from patients, Dr. Singh will investigate how these cells change their identity to grow and resist chemotherapy. He hopes that this work will define novel ways to enhance the effectiveness of current therapies and also identify new targets for treatment of pancreatic cancer.

Project title: "Epigenetic evolution of pancreatic adenocarcinoma during combination chemotherapy"
Institution: Dana-Farber Cancer Institute
Award Program: Physician-Scientist
Sponsor(s) / Mentor(s): Brian M. Wolpin, MD, MPH, and Andrew J. Aguirre, MD, PhD
Cancer Type: Pancreatic
Research Area: Epigenetics